| Primary Identifier | MGI:3822555 | Allele Type | Transgenic |
| Attribute String | Inserted expressed sequence | Gene | Tg(CTSG-NUP98/HOXA9)1589Tanak |
| Strain of Origin | (C57BL/6J x DBA/2J)F2 | Is Recombinase | false |
| Is Wild Type | false |
| description | Of five transgenic founder lines, two - designated 131 and 1589 - were maintained. The latter was chosen for detailed phenotypic characterization because of its higher incidence of leukemia (10% vs. 7% at 12 months of age). |
| molecularNote | The protein-coding sequence of this transgene was amplified from a fusion transcript that is expressed in patients with myeloid leukemias characterized by the t(7;11)(p15;p15) chromosomal translocation. The transcript, derived from the in-frame joining of the 141 bp 5' exon of NUP98 to exon 1B of HOXA9, generates a chimeric protein comprising the amino terminal half of NUP98, containing the phenylalanine-glycine (FG) repeat region, followed by most of HOXA9 including its homeodomain. The cDNA was inserted at the transcription start site of the human cathepsin G (CTSG) gene in an expression cassette containing the entire CTSG genomic sequence, including ~2.5 kb of 5' and ~0.8 kb of 3' flanking DNA, which drives expression exclusively in cells of the myeloid lineage. RT-PCR analysis detects transcripts derived from the transgene only in bone marrow and spleen. |
